AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27919356 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin monotherapy (n = 155)
Number of subjects: 552
Study 27919356 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/20 mg) + niacin (to 2 g) (N = 279)
Number of subjects: 552
Study 27919356 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 552
Study 24102228 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised ICD patient group
Number of subjects: 327
Study 24172024 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based cognitive-behavioural therapy (CBT)
Number of subjects: 1064
Study 24172024 — intervention group
Group type: COMPARATOR
Intervention: Attention control PSHE
Number of subjects: 1064
Study 24172024 — intervention group
Group type: COMPARATOR
Intervention: Usual PSHE
Number of subjects: 1064
Study 19357009 — intervention group
Group type: EXPERIMENTAL
Intervention: Revolving-door flap (RD)
Number of subjects: 40
Study 19357009 — intervention group
Group type: COMPARATOR
Intervention: Full-thickness skin graft (FTSG)
Number of subjects: 40
Study 18422535 — intervention group
Group type: EXPERIMENTAL
Intervention: Support groups
Number of subjects: 32
Study 18422535 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 15800981 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM monotherapy (group A)
Number of subjects: 37
Study 15800981 — intervention group
Group type: COMPARATOR
Intervention: Initial interferon plus LAM treatment followed by LAM monotherapy (group B)
Number of subjects: 37
Study 15800981 — intervention group
Group type: EXPERIMENTAL
Intervention: b2m elevation duration in responders (group A)
Number of subjects: 37
Study 15800981 — intervention group
Group type: EXPERIMENTAL
Intervention: b2m levels decrease at 3 months (group A)
Number of subjects: 37
Study 15800981 — intervention group
Group type: EXPERIMENTAL
Intervention: b2m status at baseline (group A)
Number of subjects: 37
Study 12356387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 400 microg plus regular margarine 25 g
Number of subjects: 152
Study 12356387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 400 microg plus sterol‐ester margarine 25 g
Number of subjects: 152
Study 12356387 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus sterol‐ester margarine 25 g (2 g of plant sterol)
Number of subjects: 152
Study 12356387 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus regular margarine 25 g
Number of subjects: 152
Study 10334346 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% ophthalmic suspension
Number of subjects: 245
Study 10334346 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1.0% ophthalmic suspension
Number of subjects: 245
Study 8567330 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX RT with 1.2 Gy twice daily, total dose of 64.8 Gy in 27 treatment days, shorter interfraction interval (4.5-5 h)
Number of subjects: 169
Study 8567330 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every week, shorter interfraction interval (4.5-5 h)
Number of subjects: 169
Study 8567330 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every other week, shorter interfraction interval (4.5-5 h)
Number of subjects: 169
Study 8567330 — intervention group
Group type: COMPARATOR
Intervention: HFX RT with 1.2 Gy twice daily, total dose of 64.8 Gy in 27 treatment days, longer interfraction interval (5.5-6 h)
Number of subjects: 169
Study 8567330 — intervention group
Group type: COMPARATOR
Intervention: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every week, longer interfraction interval (5.5-6 h)
Number of subjects: 169
Study 8567330 — intervention group
Group type: COMPARATOR
Intervention: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every other week, longer interfraction interval (5.5-6 h)
Number of subjects: 169
Study 1760051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol users
Number of subjects: 18
Study 1760051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 7036032 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue dye
Number of subjects: 63
Study 7036032 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon-14-labeled urea
Number of subjects: 63
Study 7036032 — intervention group
Group type: COMPARATOR
Intervention: Calcium-45
Number of subjects: 63
Study 7036032 — intervention group
Group type: COMPARATOR
Intervention: Iodine-125-labeled albumin
Number of subjects: 63
Study 29624749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-deprived group (N=50)
Number of subjects: 100
Study 29624749 — intervention group
Group type: COMPARATOR
Intervention: Well-rested group (N=50)
Number of subjects: 100
Study 28111908 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tocopherol acetate oil and silicone–vitamin E gauzes (group 2)
Number of subjects: 60
Study 28111908 — intervention group
Group type: COMPARATOR
Intervention: α-tocopherol acetate oil and traditional moist gauzes (group 1)
Number of subjects: 60
Study 25339518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily during the open-label maintenance (OLM) study
Number of subjects: 82
Study 25339518 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the randomized controlled trial (RCT)
Number of subjects: 82
Study 25339518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 82
Study 25339518 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 82
Study 23827131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with high omega-3 fatty acids (LFn3; 23% energy as fat)
Number of subjects: 0
Study 23827131 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF; 20% energy as fat)
Number of subjects: 0
Study 23827131 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (40% energy as fat)
Number of subjects: 0
Study 21929645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 44
Study 21929645 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 44
Study 19922613 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED-IT intervention (Internet-based weight-loss program)
Number of subjects: 65
Study 19922613 — intervention group
Group type: COMPARATOR
Intervention: Information only control group
Number of subjects: 65
Study 19922613 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED-IT intervention
Number of subjects: 65
Study 18073548 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg propofol at the end of surgery
Number of subjects: 80
Study 18073548 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 80
Study 15855580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg for 3 months
Number of subjects: 16
Study 15855580 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 16
Study 12219661 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 0
Study 12219661 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 10558391 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention program, specific details not provided.
Number of subjects: 0
Study 10558391 — intervention group
Group type: COMPARATOR
Intervention: Control group derived from participants' compliance to program instructions.
Number of subjects: 0
Study 7604145 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg BAHS before sleep for 6 months
Number of subjects: 20
Study 7604145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2356213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) at 6 hours postmorphine
Number of subjects: 6
Study 2356213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) at 24 hours postmorphine
Number of subjects: 6
Study 2356213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) at 6 and 24 hours postmorphine
Number of subjects: 6
Study 2356213 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) at 24 hours postmorphine preceded by naloxone at 6 hours
Number of subjects: 6
Study 42333 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (8 mg)
Number of subjects: 11
Study 42333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 11
Study 42333 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chlorpheniramine and cimetidine
Number of subjects: 11
Study 42333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31151425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling, nutritional supplements (rich in branched-chain amino acids), and a home-based exercise program (low-intensity daily muscle training and lifestyle education).
Number of subjects: 130
Study 31151425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling, nutritional supplements, and exercise program (as above).
Number of subjects: 130
Study 31151425 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 130
Study 28556061 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ASA intravenously
Number of subjects: 30
Study 28556061 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg enteric-coated ASA bid
Number of subjects: 30
Study 28556061 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg chewable ASA
Number of subjects: 30
Study 26033265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin (TP)
Number of subjects: 67
Study 23878192 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylazine (1.1 mg/kg)
Number of subjects: 0
Study 23878192 — intervention group
Group type: EXPERIMENTAL
Intervention: Detomidine (20 mug/kg)
Number of subjects: 0
Study 23878192 — intervention group
Group type: EXPERIMENTAL
Intervention: Medetomidine (5 mug/kg)
Number of subjects: 0
Study 23878192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (3.5 mug/kg)
Number of subjects: 0
Study 23878192 — intervention group
Group type: EXPERIMENTAL
Intervention: Romifidine (100 mug/kg)
Number of subjects: 0
Study 23878192 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 21851879 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐blockade
Number of subjects: 8988
Study 21851879 — intervention group
Group type: COMPARATOR
Intervention: β‐blockade (U.S. cohort)
Number of subjects: 8988
Study 21851879 — intervention group
Group type: COMPARATOR
Intervention: β‐blockade (ROW cohort)
Number of subjects: 8988
Study 19623203 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.5 g/day, 1.5 g/day total n-3 PUFA)
Number of subjects: 77
Study 19623203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high oleic sunflower oil)
Number of subjects: 77
Study 17444382 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment combined with cycloidal vibration therapy (Vibro‐Pulse), 30 minutes per treatment, three times per day
Number of subjects: 36
Study 17444382 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (intravenous or oral antibiotic therapy) and bed rest
Number of subjects: 36
Study 16529174 — intervention group
Group type: EXPERIMENTAL
Intervention: Superoxide anion production measured by cytochrome c reduction
Number of subjects: 56
Study 16529174 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ox-LDL autoantibody titres in gingival blood
Number of subjects: 56
Study 16529174 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-OHdG concentration in venous blood
Number of subjects: 56
Study 16529174 — intervention group
Group type: COMPARATOR
Intervention: 8-OHdG levels in gingival blood
Number of subjects: 56
Study 16529174 — intervention group
Group type: COMPARATOR
Intervention: Total antioxidant status (TAS) in venous blood serum
Number of subjects: 56
Study 16529174 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-OHdG concentration in gingival blood
Number of subjects: 56
Study 11718589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroid (fluticasone propionate)
Number of subjects: 0
Study 11718589 — intervention group
Group type: COMPARATOR
Intervention: Oral antihistamine (loratadine)
Number of subjects: 0
Study 9151795 — intervention group
Group type: EXPERIMENTAL
Intervention: cM‐T412 (chimeric CD4 monoclonal antibody)
Number of subjects: 0
Study 9151795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8197566 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (group A)
Number of subjects: 42
Study 8197566 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion with rh‐EPO (group A1)
Number of subjects: 42
Study 8197566 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood transfusion (group B)
Number of subjects: 42
Study 3069539 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.30 mg
Number of subjects: 20
Study 3069539 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 30 mg
Number of subjects: 20
Study 31982581 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg, 5 mg, or 10 mg PedPRM nightly up to 104 weeks
Number of subjects: 80
Study 31982581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2-week withdrawal period)
Number of subjects: 80
Study 31982581 — intervention group
Group type: EXPERIMENTAL
Intervention: PedPRM (2, 5, or 10 mg nightly)
Number of subjects: 80
Study 30310225 — intervention group
Group type: EXPERIMENTAL
Intervention: ENGAGE intervention delivered during routine dental check-ups to 335 patients by 18 GDPs.
Number of subjects: 1000
Study 30310225 — intervention group
Group type: COMPARATOR
Intervention: Patient survey regarding lifestyle questions asked by dentists.
Number of subjects: 1000
Study 28320223 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/day
Number of subjects: 225
Study 28320223 — intervention group
Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day
Number of subjects: 225
Study 28320223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 26275761 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-coached exposure therapy
Number of subjects: 14
Study 26275761 — intervention group
Group type: COMPARATOR
Intervention: Traditional CBT (pre-exposure anxiety management strategies)
Number of subjects: 14
Study 23114849 — intervention group
Group type: EXPERIMENTAL
Intervention: LGG plus smectite (3 g)
Number of subjects: 88
Study 23114849 — intervention group
Group type: COMPARATOR
Intervention: LGG alone (placebo)
Number of subjects: 88
Study 21420788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 16
Study 21420788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 16
Study 21420788 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen and tropisetron
Number of subjects: 16
Study 21420788 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study 18822830 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant medications
Number of subjects: 0
Study 18822830 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstimulant medications
Number of subjects: 0
Study 16642613 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding therapy
Number of subjects: 88
Study 16642613 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (medication group)
Number of subjects: 88
Study 14579046 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated NIRx stent
Number of subjects: 20
Study 11094887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐intensity infrared laser radiation to the tympanic vessels
Number of subjects: 0
Study 11094887 — intervention group
Group type: EXPERIMENTAL
Intervention: Local transcutaneous laser radiation of the affected joints
Number of subjects: 0
Study 11094887 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous laser radiation
Number of subjects: 0
Study 8669653 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with air (Group A)
Number of subjects: 30
Study 8669653 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with nitrous oxide (Group N)
Number of subjects: 30
Study 1569443 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 342
Study 1569443 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 342
Study 2857276 — intervention group
Group type: EXPERIMENTAL
Intervention: Triangular moulded rubber mask ('Rendell‐Baker')
Number of subjects: 44
Study 2857276 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular silicone rubber mask ('Laerdal')
Number of subjects: 44
Study 2857276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning with 70% ethanol
Number of subjects: 44
Study 29991122 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation together with 10 sessions of WBMF therapy
Number of subjects: 73
Study 29991122 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (control group)
Number of subjects: 73
Study 27145328 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) based on the health action process approach plus a views-on-ageing component
Number of subjects: 310
Study 27145328 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) with an additional planning task
Number of subjects: 310
Study 27145328 — intervention group
Group type: COMPARATOR
Intervention: Behaviour change techniques (BCTs) targeting volunteering
Number of subjects: 310
Study 27145328 — intervention group
Group type: COMPARATOR
Intervention: No intervention (passive control group)
Number of subjects: 310
Study 24016360 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games
Number of subjects: 25
Study 24016360 — intervention group
Group type: COMPARATOR
Intervention: Change-of-direction training
Number of subjects: 25
Study 22904565 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI cell infusion (n = 57)
Number of subjects: 163
Study 22904565 — intervention group
Group type: EXPERIMENTAL
Intervention: OMI cell infusion (n = 22)
Number of subjects: 163
Study 22904565 — intervention group
Group type: COMPARATOR
Intervention: Control group for AMI (n = 60)
Number of subjects: 163
Study 22904565 — intervention group
Group type: COMPARATOR
Intervention: Control group for OMI (n = 24)
Number of subjects: 163
Study 22904565 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell infusion group (n = 79)
Number of subjects: 163
Study 22904565 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 84)
Number of subjects: 163
Study 20515510 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace-oriented intervention for burnout
Number of subjects: 74
Study 20515510 — intervention group
Group type: COMPARATOR
Intervention: Control group (declined participation)
Number of subjects: 74
Study 18658019 — intervention group
Group type: EXPERIMENTAL
Intervention: On-field alternative warm-up program, performed 3 times per week during the fall 2002 season
Number of subjects: 1435
Study 18658019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1435
Study 15928071 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel at 175 mg/m2 plus Carboplatin at 7 AUC (Arm A)
Number of subjects: 247
Study 15928071 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel at 175 mg/m2 plus alternating Carboplatin at 7 AUC and Cisplatin at 75 mg/m2 (Arm B)
Number of subjects: 247
Study 14562186 — intervention group
Group type: EXPERIMENTAL
Intervention: Duruöz's Hand Index (DHI)
Number of subjects: 60
Study 10906292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved arteries (20% dimethylsulphoxide, stored for an average of 22 days)
Number of subjects: 120
Study 10906292 — intervention group
Group type: COMPARATOR
Intervention: Fresh-control arteries (tested for 24 hours after harvesting)
Number of subjects: 120
Study 10906292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved veins
Number of subjects: 120
Study 10906292 — intervention group
Group type: COMPARATOR
Intervention: Unfrozen veins (control)
Number of subjects: 120
Study 8826549 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mL NaCl 0.9%
Number of subjects: 18
Study 8826549 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL NaCl 0.9%
Number of subjects: 18
Study 8826549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL NaCl 0.9%
Number of subjects: 18
Study 8826549 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL NaCl 0.9%
Number of subjects: 18
Study 1598734 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiphenamil 400 mg q.i.d.
Number of subjects: 23
Study 1598734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6589660 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI)
Number of subjects: 0
Study 6589660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6589660 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI) withdrawal
Number of subjects: 0
Study 30711959 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 5099
Study 30711959 — intervention group
Group type: COMPARATOR
Intervention: No trastuzumab
Number of subjects: 5099
Study 30260246 — intervention group
Group type: EXPERIMENTAL
Intervention: New information sheet (minimising reference to falls)
Number of subjects: 4145
Study 30260246 — intervention group
Group type: COMPARATOR
Intervention: Standard information sheet
Number of subjects: 4145
Study 26566149 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim, 200 mg twice daily
Number of subjects: 30
Study 26566149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24769557 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy using the Amadeo Robotic System
Number of subjects: 20
Study 24769557 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy executed by a trained physiotherapist
Number of subjects: 20